Newron Highlights Evenamide's Clinical Benefits in Schizophrenia Treatment

Event summary

  • Newron Pharmaceuticals published peer-reviewed data in Therapeutic Advances in Psychopharmacology, highlighting clinically meaningful benefits of evenamide as an adjunctive treatment for schizophrenia.
  • Evenamide, a novel glutamate modulator, showed sustained benefits when added to first- or second-generation antipsychotics in patients with treatment-resistant schizophrenia (TRS).
  • The publication synthesizes results from multiple randomized clinical trials, providing a scientific mechanistic rationale for evenamide's use.
  • ENIGMA-TRS Phase III clinical program for evenamide was initiated in August 2025, with two studies enrolling at least 1,000 patients combined.

The big picture

Newron's publication underscores the growing interest in targeting glutamatergic signaling in schizophrenia, a mechanism largely untapped by current antipsychotics. The company's focus on TRS patients addresses a significant unmet need, potentially redefining treatment paradigms. Success in the ENIGMA-TRS program could position evenamide as a first-in-class therapy, but competition and regulatory hurdles remain critical factors.

What we're watching

Clinical Trial Progress
The pace at which ENIGMA-TRS Phase III trials will enroll and report results will determine evenamide's regulatory and commercial prospects.
Market Differentiation
Whether evenamide can sustain its favorable safety and tolerability profile while demonstrating superior efficacy against existing treatments.
Commercialization Strategy
How Newron and its partners will position evenamide in the competitive landscape of schizophrenia treatments, particularly for TRS patients.